Social network
  • Understanding science, discovering

    Understanding science and discovering

  • Developing and marketing innovative solutions

    Developing and marketing innovative solutions

  • Manufacturing and supply

    Manufacturing and supply

    Tools content (print, share, increase/decrease text size):


    Early development

    We are open to all types of partnerships that can accelerate a product’s early development, from the pre-clinical studies stage to the clinical Proof of Concept one.


    Sanofi and the Rockefeller University of New York combined efforts to develop a new treatment for Alzheimer’s disease

    Sanofi signed a global licensing agreement with the Rockefeller University of New York in 2009 to develop a novel monoclonal antibody for the treatment of Alzheimer’s disease. Targeting certain specific forms of the Amyloid Beta parenchymal plaque, the anti-Amyloid Beta (ABeta) antibody therapy is a highly attractive approach to preventing, and reversing, amyloid plaque formation. This may lead to cognitive improvement in Alzheimer’s patients.

    Sanofi obtained through this collaboration, an exclusive worldwide license to develop, manufacture and commercialize the anti-ABeta antibody. The product was in discovery phase at the time of the deal’s signing and it is now in phase I of clinical development.


    Right area:

    Go to Our Contacts  

    Upcoming Events

    From June 6 to June 9, 2016
    BIO International Convention
    US, San Francisco


    © Sanofi 2004-2017 - All rights reserved - Update: November 28, 2016

    • Site complies with W3C WCAG 2.0 (new window, in english)